Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Diagnostic Value of the Circulating Tumor Cells and Circulating Tumor-Derived Endothelial Cells Detection for Non-Small Cell Lung Cancer

Version 1 : Received: 5 January 2021 / Approved: 6 January 2021 / Online: 6 January 2021 (15:32:40 CET)

How to cite: Xie, J.; Ruan, Z.; Zheng, J.; Gong, Y.; Wang, Y.; Hu, B.; Cheng, J.; Huang, Q. Diagnostic Value of the Circulating Tumor Cells and Circulating Tumor-Derived Endothelial Cells Detection for Non-Small Cell Lung Cancer. Preprints 2021, 2021010129 (doi: 10.20944/preprints202101.0129.v1). Xie, J.; Ruan, Z.; Zheng, J.; Gong, Y.; Wang, Y.; Hu, B.; Cheng, J.; Huang, Q. Diagnostic Value of the Circulating Tumor Cells and Circulating Tumor-Derived Endothelial Cells Detection for Non-Small Cell Lung Cancer. Preprints 2021, 2021010129 (doi: 10.20944/preprints202101.0129.v1).

Abstract

Effective biomarkers are essential to the early diagnosis of non-small cell lung cancer (NSCLC). Herein, a retrospective study of 49 newly diagnosed and recurrent NSCLC patients, 31 patients with benign pulmonary disease and 24 healthy volunteers was conducted, to evaluate the diagnostic value of circulating rare cells for NSCLC. The expression of circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs) in peripheral blood were measured by subtraction enrichment-immunostaining-fluorescence in situ hybridization (SE-iFISH). The level of CTCs (P<0.001) and CTECs (P<0.001) was significantly higher in NSCLC group than that in benign pulmonary disease group. The proportion of small CTCs (P<0.001) and CTECs (P<0.0001) significantly increased from benign lung disease individuals to NSCLC patients. The AUC of ROC curves of total CTCs and CTECs were 0.815 (95%CI: 0.722~0.907), 0.739 (95%CI: 0.618~0.860), respectively. The cut-off values for discriminating NSCLC with benign lung disease patients were total CTCs 11.5 units/6ml and total CTECs 10.5 units/6ml, with sensitivity and specificity being 67.3% and 83.9%, 77.6% and 77.4%, respectively. When CTCs and CTECs were combined, predictive value significantly increased to 82.6% as measured by the area under the curve. Small CTCs and triploid CTCs had high positive predictive value (PPV) and positive likelihood ratio (LR+) of the diagnosis of NSCLC in early stage. CTCs and CTECs can not only be used as new biomarkers for the diagnosis of NSCLC, but can also improve diagnostic performance of the early stage NSCLC. Moreover, the combined examination of CTCs and CTECs is be superior to the single.

Subject Areas

Non-small cell lung cancer; Circulating tumor cells; Circulating tumor-derived endothelial cells; Biomarkers; SE-iFISH

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.